2023 USC Discovery ERRα/γ Agonist · Cardiac Exercise Mimetic Very Early Research

SLU-PP-332

ERRα/γ Agonist · Cardiac Exercise Mimetic · USC 2023

"A small molecule discovered in 2023 that activates estrogen-related receptors α and γ — producing cardiac adaptations in sedentary animals that normally only appear in trained athletes. A genuinely distinct mechanism from AICAR's AMPK pathway. Cardiac-specific. Very early stage. Not yet studied in humans."

Discovery
2023 · Bharat Bhatt lab · USC
Target
ERRα and ERRγ nuclear receptors
Key finding
Cardiac adaptations in sedentary mice without training
Human data
None — in vivo mouse only
WADA
Not yet prohibited
Discovery & What It Does

The cardiac exercise mimetic — a different pathway entirely

SLU-PP-332 was identified by Bharat Bhatt's laboratory at the University of Southern California in 2023 as part of a systematic screen for agonists of estrogen-related receptors (ERRα and ERRγ). ERRs are nuclear receptors — transcription factors that sit inside cells and directly control gene expression programmes involved in mitochondrial biogenesis, fatty acid oxidation, and cardiac energy metabolism. ERRα and ERRγ are the dominant drivers of the gene expression changes that appear in the heart after endurance training.

When SLU-PP-332 was administered to sedentary mice, it activated cardiac ERRα/γ and produced the same gene expression signature — and the same structural cardiac adaptations — normally only seen in trained athletes. The hearts of treated sedentary animals showed increased mitochondrial density, improved oxidative capacity, and resistance to age-related cardiac decline. These are not just metabolic measurements — they are architectural changes to the heart itself.

The distinction from AICAR is important: AICAR works by activating AMPK (the cellular energy sensor) and producing a broad metabolic exercise-mimetic effect across multiple tissues. SLU-PP-332 works directly at the nuclear receptor level in cardiac tissue — a fundamentally different mechanism that operates in the nucleus rather than the cytoplasm, and with more cardiac specificity than AICAR's broad metabolic effects.

Why ERRα/γ matters for cardiac ageing: ERRα/γ activity declines with age in cardiac tissue — contributing to the age-related reduction in cardiac oxidative capacity, mitochondrial function, and exercise tolerance that characterises cardiovascular ageing. SLU-PP-332 essentially switches back on the transcriptional programmes that age switches off. Whether this translates into clinically meaningful cardiac protection in humans is the central open question.

Mechanism

Nuclear receptor activation — gene programmes, not enzymes

How SLU-PP-332 Works

1
ERRα/γ nuclear receptor agonism: SLU-PP-332 binds and activates ERRα (estrogen-related receptor alpha) and ERRγ. These receptors translocate to the nucleus and bind ERR response elements in the promoters of hundreds of genes involved in cardiac metabolism, mitochondrial biogenesis, and fatty acid oxidation. Essentially: it turns on the genetic programme for a trained cardiac phenotype.
2
PGC-1α co-activation: ERRα/γ works in concert with PGC-1α (peroxisome proliferator-activated receptor gamma co-activator 1 alpha) — the master regulator of mitochondrial biogenesis. Training increases PGC-1α; SLU-PP-332 activates the transcription factors that PGC-1α co-activates, producing overlapping but distinct effects on the cardiac gene programme.
3
Cardiac structural adaptation: In sedentary mice, 4 weeks of SLU-PP-332 treatment produced: increased cardiac mitochondrial density, upregulation of fatty acid oxidation enzymes, improvement in cardiac efficiency under load, and resistance to age-related cardiac dysfunction. These are the same structural adaptations measured in marathon runners' hearts.
4
Tissue specificity: ERRα/γ are particularly highly expressed in cardiac and skeletal muscle tissue — giving SLU-PP-332 more tissue specificity than AICAR (which activates AMPK broadly across most tissues). This may translate to a better safety profile for cardiac applications specifically.
What We Don't Know

The gaps in the evidence

SLU-PP-332 was published in a single 2023 paper and has very limited follow-up research. Critical unknowns: human pharmacokinetics (the compound was only studied in mice), off-target effects of ERR agonism in non-cardiac tissues (ERRs are expressed in liver, adipose, and reproductive tissue), optimal dosing for cardiac vs metabolic effects, safety at chronic high doses, whether the cardiac structural changes are stable or revert after discontinuation, and whether the effects extend beyond cardiac tissue to skeletal muscle endurance.

The community has largely not adopted SLU-PP-332 yet — partly because it is too new, partly because it is a small molecule rather than a peptide (though it is often discussed in peptide circles), and partly because synthesis of verified SLU-PP-332 from research chemical suppliers is currently limited. This will likely change as the research matures and the compound becomes more widely available through research channels.

⚡ What to Watch

Follow-up publications from the Bhatt laboratory at USC. Any extension to human studies (Phase 1 safety trials would be the next step). WADA monitoring — if the compound reaches human trials and demonstrates performance enhancement, it will likely be added to the prohibited list (as AICAR was rapidly after its 2008 characterisation). Skeletal muscle data — does the cardiac ERR activation translate to skeletal muscle endurance improvements?

Honest Assessment

Editor's summary

SLU-PP-332 is genuinely novel science — a different mechanism from everything else in the exercise mimetic space. ERR nuclear receptor agonism produces cardiac adaptations through the gene expression level rather than enzyme activation, with more cardiac specificity than AICAR's broad metabolic effects. The 2023 mouse data is compelling. The human data is non-existent. This is one to track rather than use — the science needs time to develop, the safety needs characterisation, and the pharmacokinetics need human study before this can be evaluated as an intervention.

Verdict
"A 2023 discovery with a genuinely novel mechanism — ERRα/γ nuclear receptor agonism producing trained-athlete cardiac adaptations in sedentary animals. Distinct from AICAR. More cardiac-specific. No human data. The most interesting new exercise mimetic mechanism to emerge in years — but far too early for human use."